This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gill, I. Articles by Mazumder, A. Search for Related Content PubMed PubMed Citation Articles by Gill, I. Articles by Mazumder, A.

Synergistic Antitumor Effects of Interleukin 2 and the Monoclonal Lym-1 against Human Burkitt Lymphoma Cells in Vitro and in Vivo¹

Department of Medicine, University of Southern California Medical Center, Los Angeles, California 90033

Interleukin 2 (IL-2) regulates immune responses by inducing proliferation and differentiation of T-cells into cytotoxic cells, inducing lymphokine activated killer activity and enhancing antibody dependent cellular cytotoxicity (ADCC). Lym-1, a monoclonal antibody, recognizes a membrane antigen present on the surface of B-lymphoma cells and can be used for ADCC. We therefore used Raji (human Burkitt lymphoma) cells to study the efficacy of combination therapy with IL-2, lymphokine activated killer activity, and Lym-1. In vitro ADCC assays using Lym-1 showed that preincubation of peripheral blood lymphocytes with IL-2 had a synergistic antitumor effect. The maximum synergism was achieved when peripheral blood lymphocytes were incubated with IL-2 for 3 days as compared to 1 or 2 days, with the optimal concentration of IL-2 being 1000 units/ml. This effect was specific for Lym-1 as demonstrated by experiments using an irrelevant (antimelanoma) monoclonal antibody or an irrelevant target cell (A375). The ADCC was blocked by an anti-Fc receptor antibody (3G8). In vivo experiments performed by growing Raji tumors in nude mice also demonstrated the increase in ADCC and the synergism between IL-2 and Lym-1 in terms of decreased tumor size and growth. The mechanism of this synergy is probably from activation of cells mediating ADCC. This raises the possibility that treatment of patients with low doses of IL-2 in combination with Lym-1 may enhance immune responses and thereby antitumor activity.

¹ This work is supported by USPHS Grants CA 42962 and CA 01222.

² To whom requests for reprints should be addressed, at Norris Comprehensive Cancer Hospital, Room 624, 1441 Eastlake Avenue, Los Angeles, CA 90033.

Received 7/18/88. Revised 2/14/89. Revised 5/ 1/89. Accepted 7/ 5/89.

This article has been cited by other articles:

				J. G. Berdeja, A. Hess, D. M. Lucas, P. O'Donnell, R. F. Ambinder, L. F. Diehl, D. Carter-Brookins, S. Newton, and I. W. Flinn Systemic Interleukin-2 and Adoptive Transfer of Lymphokine-Activated Killer Cells Improves Antibody-Dependent Cellular Cytotoxicity in Patients with Relapsed B-Cell Lymphoma Treated with Rituximab Clin. Cancer Res., April 15, 2007; 13(8): 2392 - 2399. [Abstract] [Full Text] [PDF]

				L. Ottonello, A.L. Epstein, P. Dapino, P. Barbera, P. Morone, and F. Dallegri Monoclonal Lym-1 Antibody-Dependent Cytolysis by Neutrophils Exposed to Granulocyte-Macrophage Colony-Stimulating Factor: Intervention of Fc{gamma}RII (CD32), CD11b-CD18 Integrins, and CD66b Glycoproteins Blood, May 15, 1999; 93(10): 3505 - 3511. [Abstract] [Full Text] [PDF]

				J. L. Hornick, L. A. Khawli, P. Hu, M. Lynch, P. M. Anderson, and A. L. Epstein Chimeric CLL-1 Antibody Fusion Proteins Containing Granulocyte-Macrophage Colony-Stimulating Factor or Interleukin-2 With Specificity for B-Cell Malignancies Exhibit Enhanced Effector Functions While Retaining Tumor Targeting Properties Blood, June 15, 1997; 89(12): 4437 - 4447. [Abstract] [Full Text] [PDF]